Over the past 3-months we have initiated coverage on three companies; Xenon Pharmaceuticals (Nasdaq: XENE), ESSA Pharma (Nasdaq: EPIX), and Acasti Pharma (Nasdaq: ACST). After we issue our initiation reports, we generally will not issue follow-on reports, rather we will send around email updates when appropriate. This is the first such update, for two of the three names we cover, have had material changes to their business since our initiation report. For our most timely commentary, we recommend you follow us on Twitter (@encodelp), where we discuss not only names under coverage but also other names of interest in the life sciences. Read More.
Back to Research Center